利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.028 秒)

    Methodologies for the detection of human immunodeficiency virus nucleic acids employing oligonucleotide primer derived from the HIV-1 MVP5180/91 genome
    1.
    发明授权
    Methodologies for the detection of human immunodeficiency virus nucleic acids employing oligonucleotide primer derived from the HIV-1 MVP5180/91 genome 有权
    使用衍生自HIV-1 MVP5180 / 91基因组的寡核苷酸引物检测人类免疫缺陷病毒核酸的方法

    公开(公告)号：US06335158B2

    公开(公告)日：2002-01-01

    申请号：US09131551

    申请日：1998-08-10

    申请人： Stefan Brust ,  Stefan Knapp ,  Manfred Gerken ,  Lutz G. Guertler

    发明人： Stefan Brust ,  Stefan Knapp ,  Manfred Gerken ,  Lutz G. Guertler

    IPC分类号： C12Q170

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K16/1045 ,  C07K2317/21 ,  C12N2740/16022 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12Q1/703

    摘要： The present invention is directed toward nucleic-acid based methodologies for the detection of human immunodeficiency virus (HIV) nucleic acids in a sample. A novel HIV-1 isolate, designated MVP5180/91, was isolated from a West African Cameroonian patient with immunodeficiency. Nucleic acid and amino acid sequence comparisons of this isolate, with other HIV-1 strains of subtypes A-E and HIV-2 isolates, demonstrated that this virus shares only limited homology with other known HIV-1 and -2 isolates. However, this virus does display some genetic relatedness to another Cameroonian isolate designated ANT-70. These viruses form the basis for a new HIV-1 group which has been designated subtype O. An immunologically important epitope, corresponding to amino acids 601-623 of the MVP5180/91 transmembrane envelope glycoprotein, was identified. Labeled nucleic acids can be prepared from the nucleotide sequence encoding this region and employed in standard hybridization assays to detect HIV-1 nucleic acids. Alternatively, oligonucleotide primers can also be prepared from this region and employed in polymerase chain reaction (PCR) assays to detect viral-specific nucleic acids.

    摘要翻译： 本发明涉及用于检测样品中的人类免疫缺陷病毒（HIV）核酸的基于核酸的方法。 从具有免疫缺陷的西非喀麦隆患者中分离出一种名为MVP5180 / 91的新型HIV-1分离株。 该分离株与其他HIV-1亚型A-E和HIV-2分离株的核酸和氨基酸序列比较表明，该病毒与其他已知的HIV-1和-2分离株仅具有有限的同源性。 然而，这种病毒确实显示与另一个指定为ANT-70的喀麦隆分离株有一些遗传相关性。 这些病毒构成了已被指定为亚型O的新的HIV-1组的基础。鉴定了与MVP5180 / 91跨膜包膜糖蛋白的氨基酸601-623相当的免疫重要的表位。 标记的核酸可以从编码该区域的核苷酸序列制备，并用于标准杂交测定以检测HIV-1核酸。 或者，也可以从该区域制备寡核苷酸引物，并用于聚合酶链反应（PCR）测定中以检测病毒特异性核酸。

    Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS
    3.
    发明授权
    Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS 有权
    包含MVP5180 / 91表位SKGKLIS的抗原HIV gp41嵌合多肽

    公开(公告)号：US07803524B2

    公开(公告)日：2010-09-28

    申请号：US11084858

    申请日：2005-03-21

    申请人： Stefan Brust ,  Stefan Knapp ,  Manfred Gerken ,  Lutz G. Guertler

    发明人： Stefan Brust ,  Stefan Knapp ,  Manfred Gerken ,  Lutz G. Guertler

    IPC分类号： C12Q1/70 ,  A61K39/21 ,  B01L3/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K16/1045 ,  C07K2317/21 ,  C12N2740/16022 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12Q1/703

    摘要： Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.

    摘要翻译： 描述了衍生自具有名称MVP5180 / 91的新型免疫缺陷病毒的免疫活性肽。 还描述了含有这种肽的诊断组合物和使用这种诊断组合物检测引起免疫缺陷的逆转录病毒抗体的方法。 还描述了含有免疫活性肽的试剂盒。 描述了使用免疫活性肽免疫哺乳动物抗HIV感染的免疫原和方法。 还描述了编码肽的DNA和检测编码HIV病毒的核酸的方法。

    Semisynthetic diastereomerically pure N-glycidylanthracyclines, a process for the stereoselective preparation thereof as the use thereof as cytostatics
    6.
    发明授权
    Semisynthetic diastereomerically pure N-glycidylanthracyclines, a process for the stereoselective preparation thereof as the use thereof as cytostatics 失效
    半合成非对映异构体纯的N-缩水甘油环内酯，其作为细胞抑制剂的用途的立体选择性制备方法

    公开(公告)号：US5602108A

    公开(公告)日：1997-02-11

    申请号：US464468

    申请日：1995-06-05

    申请人： Manfred Gerken ,  Monika Grimm ,  Ernst Raab ,  Dieter Hoffmann ,  Reiner Straub

    发明人： Manfred Gerken ,  Monika Grimm ,  Ernst Raab ,  Dieter Hoffmann ,  Reiner Straub

    IPC分类号： A61K31/65 ,  A61K31/70 ,  A61K31/704 ,  A61P35/00 ,  C07B53/00 ,  C07C15/62 ,  C07C50/36 ,  C07H15/252 ,  C07H15/26 ,  A61K37/00 ,  C07M15/24

    CPC分类号： C07H15/26 ,  C07H15/252

    摘要： Semisynthetic diastereomerically pure N-glycidylanthracyclines, a process for the stereoselective preparation thereof and the use thereof as cytostatics. The invention relates to anthracyclines having cytostatic activity and the formula I, which are, where appropriate, in the form of a salt with an inorganic or organic acid, ##STR1## in which R.sup.1 is hydrogen or a hydroxyl group,R.sup.2 is hydrogen, a hydroxyl group or an alkyloxy group (C.sub.1 -C.sub.4),R.sup.3 is hydrogen, a hydroxyl group or a structure of the formula II ##STR2## R.sup.4 is CH.sub.2 CH.sub.3, COCH.sub.3, COCH.sub.2 OH, CHOHCH.sub.3 or CHOHCH.sub.2 OH,R.sup.5 is hydrogen, a hydroxyl group, a methoxycarbonyl group or a structure of the formula II,R.sup.6 is hydrogen, an alkyl group (C.sub.1 -C.sub.4), an allyl group, a benzyl group or mono- or di-methyloxy-substituted benzyl group, a tetrahydropyranyl group,R.sup.7 is hydrogen, an alkyl group (C.sub.1 -C.sub.4), an allyl group, a benzyl group or mono- or di-methyloxy-substituted benzyl group andR.sup.8 is a structure of the formula III or IV ##STR3## and to a process for the preparation of these compounds, which comprises reacting an anthracycline derivative of the structure I in whichR.sup.1, R.sup.2 and R.sup.4 are as defined above, andR.sup.3 is hydrogen, a hydroxyl group or a structure of the formula V ##STR4## R.sup.5 is hydrogen, a hydroxyl group, a methoxycarbonyl group or a structure of the formula V andR.sup.6 and R.sup.7 are as defined above, with (R)- or (S)-glycidyl sulfonate.

    摘要翻译： 半合成非对映体纯N-缩水甘油环素，其立体选择性制备方法及其作为细胞抑制剂的用途。 本发明涉及具有细胞抑制活性的蒽环类抗生素和式I，它们在适当的情况下为无机或有机酸形式的盐，其中R 1为氢或羟基，R 2为氢， 羟基或烷氧基（C 1 -C 4），R 3是氢，羟基或式II的结构。R 4是CH 2 CH 3，COCH 3，COCH 2 OH，CHOHCH 3或CHOHCH 2 OH，R 5是氢，羟基 ，甲氧基羰基或式II的结构，R6是氢，烷基（C1-C4），烯丙基，苄基或单 - 或二 - 甲氧基取代的苄基，四氢吡喃基，R7是 氢，烷基（C1-C4），烯丙基，苄基或单 - 或二 - 甲氧基取代的苄基，R8是式III或IV的结构，IV和 一种制备这些化合物的方法，其包括使结构I的蒽环衍生物与其中R 1，R 2和/ R 4如上定义，并且R 3是氢，羟基或式V R 5的结构是氢，羟基，甲氧基羰基或式V和R 6和R 7的结构如上定义 （R） - 或（S） - 磺酰基磺酰基。

    Anthracycline derivatives having cytostatic activity
    9.
    发明授权
    Anthracycline derivatives having cytostatic activity 失效
    具有细胞抑制活性的蒽环类衍生物

    公开(公告)号：US4948880A

    公开(公告)日：1990-08-14

    申请号：US129006

    申请日：1987-12-04

    申请人： Peter Hermentin ,  Michael Paal ,  Hans P. Kraemer ,  Cenek Kolar ,  Dieter Hoffmann ,  Manfred Gerken ,  Hans G. Berscheid ,  Dirk Bottger

    发明人： Peter Hermentin ,  Michael Paal ,  Hans P. Kraemer ,  Cenek Kolar ,  Dieter Hoffmann ,  Manfred Gerken ,  Hans G. Berscheid ,  Dirk Bottger

    IPC分类号： A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  C07H15/252

    CPC分类号： C07H15/252

    摘要： The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, which are optionally in the form of a salt of an inorganic or organic acid, ##STR1## in which the substituents have the following meaning: R.sup.1 is hydrogen or a hydroxyl group,R.sup.2 is hydrogen or a hydroxyl or a methoxy group,R.sup.3 is hydrogen or a hydroxyl group,R.sup.4 is hydrogen or a hydroxyl group,R.sup.5 is hydrogen, a hydroxyl or a methoxycarbonyl group, or a substituent of the general formula II, ##STR2## in which R.sup.8a has the meaning indicated for R.sup.8, or a substituent of the formula III, ##STR3## R.sup.6 is ethyl, methylcarbonyl, hydroxymethylcarbonyl, hydroxyalkyl or a dihydroxyalkyl,R.sup.7 is hydrogen or a substituent of the general formula IV, ##STR4## and R.sup.8 is hydrogen or a cyanomethyl group or a substituent of the general formula COR.sup.9 or CH.sub.2 R.sup.10, R.sup.9 being hydrogen, CH.sub.3, CF.sub.3 or CCl.sub.3, and R.sup.10 being C.sub.1 - to C.sub.8 -alkyl, substituted alkyl, phenyl or substituted phenyl, to a process for their preparation and to their use in pharmaceuticals.

    摘要翻译： 本发明涉及具有细胞抑制活性的新型蒽环类衍生物和通式I，其任选呈无机或有机酸盐的形式，其中取代基具有以下含义：R 1为氢或 羟基，R2是氢或羟基或甲氧基，R3是氢或羟基，R4是氢或羟基，R5是氢，羟基或甲氧基羰基或通式II的取代基， 其中R8a具有对于R8表示的含义或式III的取代基，其中R 6是乙基，甲基羰基，羟甲基羰基，羟基烷基或二羟基烷基，R 7是氢或通式IV的取代基 IV和R8是氢或氰基甲基或通式为COR9或CH2R10的取代基，R9为氢，CH3，CF3或CCl3，R10为C1-至C8-烷基，取代的烷基，苯基或取代的 苯基，为一种方法 他们的准备和在药物中的使用。